Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nathan J. Cox"'
Autor:
Nathan J. Cox, Peter M. Luo, Timothy J. Smith, Brittany J. Bisnett, Erik J. Soderblom, Michael Boyce
Publikováno v:
Frontiers in Endocrinology, Vol 9 (2018)
O-linked β-N-acetylglucosamine (O-GlcNAc) is an abundant and essential intracellular form of protein glycosylation in animals and plants. In humans, dysregulation of O-GlcNAcylation occurs in a wide range of diseases, including cancer, diabetes, and
Externí odkaz:
https://doaj.org/article/7d169bf0fd414700a3cf6ca7c1ca19b7
Autor:
Timothy J. Smith, Nathan J. Cox, Maria A. Schumacher, Wenjie Zeng, Erik J. Soderblom, Clifford A. Toleman, Seok-Ho Yu, Amberlyn M. Wands, Jennifer J. Kohler, Michael Boyce
Publikováno v:
Proceedings of the National Academy of Sciences. 115:5956-5961
O-GlcNAc is an intracellular posttranslational modification that governs myriad cell biological processes and is dysregulated in human diseases. Despite this broad pathophysiological significance, the biochemical effects of most O-GlcNAcylation event
Autor:
Anjon Audhya, Timothy J. Smith, Ela W. Knapik, Michael G. Hanna, Gokhan Unlu, Brett M Condon, Nathan J. Cox, Thomas R. Meister, Abhishek Chhetri, Peter M Luo, Erik J. Soderblom, Brittany J. Bisnett, Michael Boyce
Publikováno v:
Biochemistry. 57:91-107
The COPII coat complex, which mediates secretory cargo trafficking from the endoplasmic reticulum, is a key control point for subcellular protein targeting. Because misdirected proteins cannot function, protein sorting by COPII is critical for establ
Publikováno v:
The FASEB Journal. 34:1-1
Autor:
Lee M. Graves, Nathan J. Cox, Brian J. Dewar, Katherine Tech, Ekhson Holmuhamedov, Michael P. East, Denis O. Okumu, Ian M. McDonald, Lucas J. Aponte-Collazo, Jeffrey M. Macdonald, Andrey P. Tikunov
Publikováno v:
Biochim Biophys Acta Gen Subj
BACKGROUND: Imatinib mesylate (imatinib) is the first-line treatment for newly diagnosed chronic myeloid leukemia (CML) due to its remarkable hematologic and cytogenetic responses. We previously demonstrated that the imatinib-resistant CML cells (Myl
Autor:
Timothy J. Smith, Nathan J. Cox, Erik J. Soderblom, Peter M Luo, Brittany J. Bisnett, Michael Boyce
Publikováno v:
Frontiers in Endocrinology, Vol 9 (2018)
Frontiers in Endocrinology
Frontiers in Endocrinology
O-linked β-N-acetylglucosamine (O-GlcNAc) is an abundant and essential intracellular form of protein glycosylation in animals and plants. In humans, dysregulation of O-GlcNAcylation occurs in a wide range of diseases, including cancer, diabetes, and
Publikováno v:
Chemical Biology of Glycoproteins ISBN: 9781782623335
O-Linked β-N-acetylglucosamine (O-GlcNAc) is a critical intracellular post-translational modification, decorating thousands of nuclear, cytoplasmic, and mitochondrial proteins. O-GlcNAc governs myriad aspects of cell physiology, including cell-cycle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b9a673508951280df2a38ee087e5004
https://doi.org/10.1039/9781782623823-00094
https://doi.org/10.1039/9781782623823-00094
Autor:
Jian Jin, David M. Smalley, Albert S. Baldwin, Sreerupa Ghose Roy, Matthew J. Cooper, Thien Nguyen, James S. Duncan, Richard I. Christopherson, Gary L. Johnson, Nathan J. Cox, Brian J. Dewar, Lee M. Graves, Stephen V. Frye, Lauren S. Jones, Pei Fen Kuan, Eric I. Zimmerman, Martin C. Whittle, Kristy L. Richards
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 6, p e66755 (2013)
PLoS ONE, Vol 8, Iss 6, p e66755 (2013)
Protein kinases play key roles in oncogenic signaling and are a major focus in the development of targeted cancer therapies. Imatinib, a BCR-Abl tyrosine kinase inhibitor, is a successful front-line treatment for chronic myelogenous leukemia (CML). H
Autor:
Nathaniel J. Moorman, Kristy L. Richards, Thien Nguyen, Mark E. Cooper, Lee M. Graves, Nathan J. Cox, Thomas C. Shea, Andrea Dean
Publikováno v:
Blood. 120:2437-2437
Abstract 2437 Background: Acute myeloid leukemia (AML) remains a devastating disease. This is mainly due to limited treatment options for patients with relapsed or refractory disease and those with FMS-like tyrosine kinase 3 (FLT3) internal tandem du
Autor:
Matthew J Cooper, Nathan J Cox, Eric I Zimmerman, Brian J Dewar, James S Duncan, Martin C Whittle, Thien A Nguyen, Lauren S Jones, Sreerupa Ghose Roy, David M Smalley, Pei Fen Kuan, Kristy L Richards, Richard I Christopherson, Jian Jin, Stephen V Frye, Gary L Johnson, Albert S Baldwin, Lee M Graves
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66755 (2013)
Protein kinases play key roles in oncogenic signaling and are a major focus in the development of targeted cancer therapies. Imatinib, a BCR-Abl tyrosine kinase inhibitor, is a successful front-line treatment for chronic myelogenous leukemia (CML). H
Externí odkaz:
https://doaj.org/article/5e341c4d37844eceabaaf81238a3ae18